GRI Bio (GRI) announced the completion of patient enrollment for its Phase 2a study evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis, IPF. “We are pleased to complete enrollment of this important trial and take another step toward potentially providing a much needed treatment option for patients with IPF. Looking ahead, we remain on track to report 6-week interim biomarker results in July 2025, followed by topline data expected in the third quarter of this year. Our team is diligently working to bring this trial across the finish line and we look forward to providing updates in the near future,” commented Marc Hertz, PhD, Chief Executive Officer of GRI Bio.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GRI:
- GRI Bio Announces Positive Interim Phase 2a Results
- GRI Bio reports 6-week interim safety data from Phase 2a study of GRI-0621
- Optimistic Buy Rating for GRI Bio Driven by Promising Clinical Developments and Safety Profile
- GRI Bio Expands Share Offering Agreement
- GRI Bio presents preclinical data on GRI-0621